$TEVA

2018 Q3 Form 10-Q Financial Statement

#000119312518315734 Filed on November 01, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2017 Q3
Revenue $4.529B $5.611B
YoY Change -19.28% 0.86%
Cost Of Revenue $2.508B $2.967B
YoY Change -15.47% 7.42%
Gross Profit $1.977B $2.599B
YoY Change -23.93% -7.21%
Gross Profit Margin 43.65% 46.32%
Selling, General & Admin $1.052B $1.215B
YoY Change -13.42% -2.8%
% of Gross Profit 53.21% 46.75%
Research & Development $311.0M $531.0M
YoY Change -41.43% -19.91%
% of Gross Profit 15.73% 20.43%
Depreciation & Amortization $474.0M $527.0M
YoY Change -10.06% -8.67%
% of Gross Profit 23.98% 20.28%
Operating Expenses $1.363B $1.746B
YoY Change -21.94% 40.81%
Operating Profit $16.00M $378.0M
YoY Change -95.77% -75.78%
Interest Expense -$257.0M -$235.0M
YoY Change 9.36% 56.67%
% of Operating Profit -1606.25% -62.17%
Other Income/Expense, Net -$229.0M -$259.0M
YoY Change -11.58%
Pretax Income -$213.0M $119.0M
YoY Change -278.99% -80.65%
Income Tax -$26.00M -$494.0M
% Of Pretax Income -415.13%
Net Earnings -$208.0M $595.0M
YoY Change -134.96% 44.42%
Net Earnings / Revenue -4.59% 10.6%
Basic Earnings Per Share -$0.27 $0.52
Diluted Earnings Per Share -$0.27 $0.52
COMMON SHARES
Basic Shares Outstanding 1.018B shares 1.017B shares
Diluted Shares Outstanding 1.018B shares 1.017B shares

Balance Sheet

Concept 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.875B $680.0M
YoY Change 175.74% -56.33%
Cash & Equivalents $1.875B $680.0M
Short-Term Investments
Other Short-Term Assets $483.0M $3.062B
YoY Change -84.23% 27.11%
Inventory $4.866B $5.060B
Prepaid Expenses $911.0M
Receivables $5.665B $7.424B
Other Receivables $0.00 $0.00
Total Short-Term Assets $13.88B $16.23B
YoY Change -14.45% -6.67%
LONG-TERM ASSETS
Property, Plant & Equipment $7.101B $8.001B
YoY Change -11.25% -4.51%
Goodwill $27.59B
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $722.0M $1.585B
YoY Change -54.45% -49.34%
Total Long-Term Assets $51.18B $69.86B
YoY Change -26.73% -14.14%
TOTAL ASSETS
Total Short-Term Assets $13.88B $16.23B
Total Long-Term Assets $51.18B $69.86B
Total Assets $65.06B $86.08B
YoY Change -24.42% -12.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.626B $2.370B
YoY Change -31.39% -52.15%
Accrued Expenses $2.944B $3.295B
YoY Change -10.65%
Deferred Revenue
YoY Change
Short-Term Debt $515.0M $827.0M
YoY Change -37.73%
Long-Term Debt Due $2.158B $1.904B
YoY Change 13.34% -48.2%
Total Short-Term Liabilities $14.83B $16.94B
YoY Change -12.47% -12.15%
LONG-TERM LIABILITIES
Long-Term Debt $26.79B $31.97B
YoY Change -16.2% -3.64%
Other Long-Term Liabilities $1.803B $1.960B
YoY Change -8.01% 40.8%
Total Long-Term Liabilities $31.10B $33.93B
YoY Change -8.35% -1.85%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.83B $16.94B
Total Long-Term Liabilities $31.10B $33.93B
Total Liabilities $45.93B $57.41B
YoY Change -20.0% -9.76%
SHAREHOLDERS EQUITY
Retained Earnings -$3.072B
YoY Change
Common Stock $54.00M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $4.146B
YoY Change
Treasury Stock Shares 106.0M shares
Shareholders Equity $17.73B $28.67B
YoY Change
Total Liabilities & Shareholders Equity $65.06B $86.08B
YoY Change -24.42% -12.83%

Cashflow Statement

Concept 2018 Q3 2017 Q3
OPERATING ACTIVITIES
Net Income -$208.0M $595.0M
YoY Change -134.96% 44.42%
Depreciation, Depletion And Amortization $474.0M $527.0M
YoY Change -10.06% -8.67%
Cash From Operating Activities $421.0M $155.0M
YoY Change 171.61% -89.39%
INVESTING ACTIVITIES
Capital Expenditures -$139.0M -$212.0M
YoY Change -34.43% -4.07%
Acquisitions
YoY Change
Other Investing Activities $486.0M $956.0M
YoY Change -49.16% -102.98%
Cash From Investing Activities $347.0M $744.0M
YoY Change -53.36% -102.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -705.0M -825.0M
YoY Change -14.55% -103.25%
NET CHANGE
Cash From Operating Activities 421.0M 155.0M
Cash From Investing Activities 347.0M 744.0M
Cash From Financing Activities -705.0M -825.0M
Net Change In Cash 63.00M 74.00M
YoY Change -14.86% -101.35%
FREE CASH FLOW
Cash From Operating Activities $421.0M $155.0M
Capital Expenditures -$139.0M -$212.0M
Free Cash Flow $560.0M $367.0M
YoY Change 52.59% -78.18%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2005Q1 teva Annual Sales Of Lamictal
AnnualSalesOfLamictal
950000000
CY2008Q3 teva Annual Sales Of Lamictal
AnnualSalesOfLamictal
2300000000
CY2009Q1 teva Annual Sales At Time Of Settlement
AnnualSalesAtTimeOfSettlement
350000000
CY2013Q4 teva Annual Sales Of Lidoderm
AnnualSalesOfLidoderm
1200000000
CY2014Q1 teva Punitive Damages
PunitiveDamages
17900000
CY2015Q2 teva Modafinil Payment
ModafinilPayment
1200000000
CY2017Q2 teva Damages Assessment
DamagesAssessment
235500000
CY2013Q3 teva Compensatory Damages And Penalties
CompensatoryDamagesAndPenalties
12400000
CY2013Q3 teva Annual Sales Of Lidoderm
AnnualSalesOfLidoderm
1400000000
CY2016Q3 teva Settlement Gain Position
SettlementGainPosition
41000000
CY2017Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
680000000
CY2017Q3 teva Beneficial Interest Obtained In Exchange For Securitized Trade Receivables
BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables
911000000
CY2018Q3 us-gaap Assets Current
AssetsCurrent
13881000000
CY2018Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5665000000
CY2018Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4875000000
CY2018Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
23404000000
CY2018Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1626000000
CY2018Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2335000000
CY2018Q3 us-gaap Assets
Assets
65061000000
CY2018Q3 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
81000000
CY2018Q3 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
3179000000
CY2018Q3 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
717000000
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1875000000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1875000000
CY2018Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2495000000 shares
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.10
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1125000000 shares
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
54000000
CY2018Q3 us-gaap Debt Current
DebtCurrent
2673000000
CY2018Q3 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
27389000000
CY2018Q3 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
427000000
CY2018Q3 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
2478000000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1366000000
CY2018Q3 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
110000000
CY2018Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
712000000
CY2018Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
699000000
CY2018Q3 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
1200000000
CY2018Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
9214000000
CY2018Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
24559000000
CY2018Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
15345000000
CY2018Q3 us-gaap Goodwill
Goodwill
27585000000
CY2018Q3 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
18300000000
CY2018Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
609000000
CY2018Q3 us-gaap Inventory Net
InventoryNet
4866000000
CY2018Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2679000000
CY2018Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1395000000
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
14830000000
CY2018Q3 us-gaap Land
Land
361000000
CY2018Q3 us-gaap Liabilities
Liabilities
45927000000
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
65061000000
CY2018Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
31097000000
CY2018Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
2158000000
CY2018Q3 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
26816000000
CY2018Q3 us-gaap Minority Interest
MinorityInterest
1404000000
CY2018Q3 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
663000000
CY2018Q3 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
5783000000
CY2018Q3 us-gaap Other Assets Current
OtherAssetsCurrent
483000000
CY2018Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
722000000
CY2018Q3 us-gaap Other Inventory In Transit
OtherInventoryInTransit
183000000
CY2018Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
911000000
CY2018Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
886000000
CY2018Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1803000000
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7101000000
CY2018Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.10
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q3 us-gaap Preferred Stock Value
PreferredStockValue
3825000000
CY2018Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
3700000 shares
CY2018Q3 us-gaap Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
2115000000
CY2018Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11976000000
CY2018Q3 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Inception To Date
RestructuringAndRelatedCostNumberOfPositionsEliminatedInceptionToDate
9100000000 Positions
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3072000000
CY2018Q3 us-gaap Restructuring Reserve
RestructuringReserve
284000000
CY2018Q3 us-gaap Senior Notes
SeniorNotes
29054000000
CY2018Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
19134000000
CY2018Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
106000000 shares
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
17730000000
CY2018Q3 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
6872000000
CY2018Q3 us-gaap Treasury Stock Value
TreasuryStockValue
4146000000
CY2018Q3 teva Accrued Expenses
AccruedExpenses
2232000000
CY2018Q3 teva Sales Reserves And Allowances
SalesReservesAndAllowances
6701000000
CY2018Q3 teva Long Term Derivative Instruments
LongTermDerivativeInstruments
24000000
CY2018Q3 teva Long Term Debentures
LongTermDebentures
6000000
CY2018Q3 teva Modafinil Euro Sales
ModafinilEuroSales
46500000
CY2018Q3 teva Payments On Account
PaymentsOnAccount
538000000
CY2018Q3 teva Beneficial Interest Obtained In Exchange For Securitized Trade Receivables
BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables
1345000000
CY2018Q3 teva Long Term Debt Currency Portion Chf
LongTermDebtCurrencyPortionCHF
0.03 pure
CY2018Q3 teva Long Term Debt Currency Portion Eur
LongTermDebtCurrencyPortionEUR
0.34 pure
CY2018Q3 teva Long Term Debt Currency Portion Usd
LongTermDebtCurrencyPortionUSD
0.63 pure
CY2018Q3 teva Fair Value Assumption Possible Increase In Risk Free Interest Rate
FairValueAssumptionPossibleIncreaseInRiskFreeInterestRate
0.005 pure
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1018711443 shares
CY2014Q4 teva Annual Sales Of Intuniv
AnnualSalesOfIntuniv
327000000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
988000000
CY2016Q4 teva Annual Sales Of Intuniv
AnnualSalesOfIntuniv
335000000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
15382000000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7128000000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4505000000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
23479000000
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2069000000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1848000000
CY2017Q4 us-gaap Assets
Assets
70615000000
CY2017Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
566000000
CY2017Q4 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
3329000000
CY2017Q4 us-gaap Business Combination Contingent Consideration Liability
BusinessCombinationContingentConsiderationLiability
735000000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
963000000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
963000000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
2495000000 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.10
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1124000000 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
54000000
CY2017Q4 us-gaap Debt Current
DebtCurrent
3646000000
CY2017Q4 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
26172000000
CY2017Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
574000000
CY2017Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
3277000000
CY2017Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
106000000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
549000000
CY2017Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
717000000
CY2017Q4 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
254000000
CY2017Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8331000000
CY2017Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
25971000000
CY2017Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
17640000000
CY2017Q4 us-gaap Goodwill
Goodwill
28414000000
CY2017Q4 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
18000000000
CY2017Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
597000000
CY2017Q4 us-gaap Inventory Net
InventoryNet
4924000000
CY2017Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2689000000
CY2017Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1454000000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17921000000
CY2017Q4 us-gaap Land
Land
390000000
CY2017Q4 us-gaap Liabilities
Liabilities
51870000000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
70615000000
CY2017Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
38000000
CY2017Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
33949000000
CY2017Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2880000000
CY2017Q4 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
28829000000
CY2017Q4 us-gaap Minority Interest
MinorityInterest
1386000000
CY2017Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
1232000000
CY2017Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
5809000000
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
701000000
CY2017Q4 us-gaap Notes Payable
NotesPayable
3426000000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
932000000
CY2017Q4 us-gaap Other Inventory In Transit
OtherInventoryInTransit
184000000
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1100000000
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
724000000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1843000000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7673000000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.10
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
3631000000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
3700000 shares
CY2017Q4 us-gaap Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
2016000000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12178000000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3808000000
CY2017Q4 us-gaap Restructuring Reserve
RestructuringReserve
311000000
CY2017Q4 us-gaap Senior Notes
SeniorNotes
28367000000
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
18745000000
CY2017Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
107000000 shares
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
17359000000
CY2017Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
8077000000
CY2017Q4 us-gaap Treasury Stock Value
TreasuryStockValue
4149000000
CY2017Q4 teva Accrued Expenses
AccruedExpenses
3014000000
CY2017Q4 teva Sales Reserves And Allowances
SalesReservesAndAllowances
7881000000
CY2017Q4 teva Long Term Derivative Instruments
LongTermDerivativeInstruments
2000000
CY2017Q4 teva Long Term Debentures
LongTermDebentures
20000000
CY2017Q4 teva Payments On Account
PaymentsOnAccount
634000000
CY2017Q3 teva Annual Sales Of Effexor
AnnualSalesOfEffexor
2600000000
CY2015Q3 teva Annual Sales Of Aggrenox
AnnualSalesOfAggrenox
455000000
teva Annual Sales Of Namenda
AnnualSalesOfNamenda
1400000000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
59000000 shares
us-gaap Adjustment For Amortization
AdjustmentForAmortization
1088000000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
564000000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1088000000
us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
87000000
us-gaap Cash Flows Between Transferor And Transferee Beneficial Interest
CashFlowsBetweenTransferorAndTransfereeBeneficialInterest
962000000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
75000000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-308000000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3768000000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-3693000000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8643000000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1584000000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.85
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36000000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.85
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
-324000000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
6100000000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1101000000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
564000000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-5171000000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-10000000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-462000000
us-gaap Gross Profit
GrossProfit
8344000000
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
409000000
us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
1717000000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-9000000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4925000000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-704000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1534000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3244000000
us-gaap Net Income Loss
NetIncomeLoss
-4730000000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
11000000
us-gaap Other Comprehensive Income Loss Finalization Of Pension And Non Pension Postretirement Plan Valuation Net Of Tax
OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax
-12000000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1026000000
us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax
118000000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1136000000
us-gaap Operating Income Loss
OperatingIncomeLoss
-4467000000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
20000000
us-gaap Other Income
OtherIncome
100000000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
195000000
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
814000000
us-gaap Payments Of Dividends Minority Interest
PaymentsOfDividendsMinorityInterest
38000000
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
195000000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
-43000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
607000000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
277000000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
507000000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-69000000
us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
-1630000000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1607000000
us-gaap Profit Loss
ProfitLoss
-4719000000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
175000000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1005000000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1432000000
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
239000000
us-gaap Restructuring Charges
RestructuringCharges
300000000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16987000000
us-gaap Share Based Compensation
ShareBasedCompensation
106000000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2745000000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1016000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1016000000 shares
teva Other Operating Income Net
OtherOperatingIncomeNet
17000000
teva Contingent Consideration Related Costs
ContingentConsiderationRelatedCosts
179000000
teva Forward Starting Interest Rate Swaps And Treasury Lock Agreements Losses
ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses
20000000
teva Profit From Sale Of Long Lived Assets And Investment
ProfitFromSaleOfLongLivedAssetsAndInvestment
48000000
teva Payment To Acquire Marketable Securities And Other Assets
PaymentToAcquireMarketableSecuritiesAndOtherAssets
194000000
teva Gain From Currency Swap
GainFromCurrencySwap
8000000
teva Interest Rate Swap Gain
InterestRateSwapGain
5000000
teva Deferred Income Taxes Net And Uncertain Tax Positions
DeferredIncomeTaxesNetAndUncertainTaxPositions
-733000000
teva Costs Related To Regulatory Actions Taken In Facilities
CostsRelatedToRegulatoryActionsTakenInFacilities
48000000
teva Legal Settlements Loss Contingencies Impairments Other Expenses
LegalSettlementsLossContingenciesImpairmentsOtherExpenses
79000000
teva Impairment And Restructuring
ImpairmentAndRestructuring
1209000000
teva Legal Settlements And Loss Contingencies
LegalSettlementsAndLossContingencies
324000000
teva Purchase Of Research And Development In Process
PurchaseOfResearchAndDevelopmentInProcess
176000000
teva Venezuela Impairment Of Net Monetary Assets
VenezuelaImpairmentOfNetMonetaryAssets
45000000
teva Inventory Step Up
InventoryStepUp
67000000
teva Other Unallocated Amounts
OtherUnallocatedAmounts
143000000
teva Patented Medicines Regulations And Similar Payments
PatentedMedicinesRegulationsAndSimilarPayments
83000000
teva Impairments Restructuring And Others
ImpairmentsRestructuringAndOthers
1209000000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
68000000 shares
us-gaap Adjustment For Amortization
AdjustmentForAmortization
909000000
dei Amendment Flag
AmendmentFlag
false
us-gaap Asset Impairment Charges
AssetImpairmentCharges
1501000000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
909000000
us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
9000000
us-gaap Cash Flows Between Transferor And Transferee Beneficial Interest
CashFlowsBetweenTransferorAndTransfereeBeneficialInterest
1372000000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
20000000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
912000000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
249000000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
269000000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
7865000000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Document Type
DocumentType
10-Q
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1460000000
us-gaap Derivative Loss On Derivative
DerivativeLossOnDerivative
493000000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.53
dei Entity Central Index Key
EntityCentralIndexKey
0000818686
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-107000000
dei Entity Registrant Name
EntityRegistrantName
TEVA PHARMACEUTICAL INDUSTRIES LTD
dei Entity Small Business
EntitySmallBusiness
false
dei Document Period End Date
DocumentPeriodEndDate
2018-09-30
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.53
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P11Y
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
9000000
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
114000000
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
1239000000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
300000000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
954000000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1501000000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
791000000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-76000000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-56000000
us-gaap Gross Profit
GrossProfit
6430000000
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
1246000000
us-gaap Impairment Of Investments
ImpairmentOfInvestments
103000000
us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
1521000000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
8000000
us-gaap Inventory Recall Expense
InventoryRecallExpense
46000000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
541000000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-736000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1792000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2852000000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2079000000
us-gaap Net Income Loss
NetIncomeLoss
736000000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
35000000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-502000000
us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax
-75000000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-577000000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3 Segment
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
3 Segment
us-gaap Operating Income Loss
OperatingIncomeLoss
1527000000
us-gaap Other Income
OtherIncome
334000000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
195000000
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
12000000
us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
10000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
438000000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-34000000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
4434000000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-13000000
us-gaap Proceeds From Repayments Of Short Term Debt
ProceedsFromRepaymentsOfShortTermDebt
-262000000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
880000000
us-gaap Profit Loss
ProfitLoss
771000000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54000000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
6989000000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
918000000
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
82000000
us-gaap Restructuring Charges
RestructuringCharges
442000000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14295000000
us-gaap Share Based Compensation
ShareBasedCompensation
122000000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2224000000
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
255000000
dei Trading Symbol
TradingSymbol
TEVA
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1020000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1018000000 shares
us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
15703000000
teva Other Operating Income Net
OtherOperatingIncomeNet
16000000
teva Contingent Consideration Related Costs
ContingentConsiderationRelatedCosts
84000000
teva Finite Lived Intangible Assets Transferred From In Process Research And Development To Product Rights
FiniteLivedIntangibleAssetsTransferredFromInProcessResearchAndDevelopmentToProductRights
553000000
teva Utilization And Other
UtilizationAndOther
469000000
teva Transactions Termination Loss Settled
TransactionsTerminationLossSettled
242000000
teva Forward Starting Interest Rate Swaps And Treasury Lock Agreements Losses
ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses
21000000
teva Profit From Sale Of Long Lived Assets And Investment
ProfitFromSaleOfLongLivedAssetsAndInvestment
53000000
teva Payment To Acquire Marketable Securities And Other Assets
PaymentToAcquireMarketableSecuritiesAndOtherAssets
56000000
teva Gain From Currency Swap
GainFromCurrencySwap
22000000
teva Interest Rate Swap Gain
InterestRateSwapGain
5000000
teva Deferred Income Taxes Net And Uncertain Tax Positions
DeferredIncomeTaxesNetAndUncertainTaxPositions
-650000000
teva Costs Related To Regulatory Actions Taken In Facilities
CostsRelatedToRegulatoryActionsTakenInFacilities
6000000
teva Legal Settlements Loss Contingencies Impairments Other Expenses
LegalSettlementsLossContingenciesImpairmentsOtherExpenses
44000000
teva Impairment And Restructuring
ImpairmentAndRestructuring
2080000000
teva Legal Settlements And Loss Contingencies
LegalSettlementsAndLossContingencies
-1239000000
teva Purchase Of Research And Development In Process
PurchaseOfResearchAndDevelopmentInProcess
82000000
teva Valuation Allowances And Reserves Foreign Currency Translation
ValuationAllowancesAndReservesForeignCurrencyTranslation
-38000000
teva Other Unallocated Amounts
OtherUnallocatedAmounts
226000000
teva Patented Medicines Regulations And Similar Payments
PatentedMedicinesRegulationsAndSimilarPayments
195000000
teva Restructuring Plan Period
RestructuringPlanPeriod
P2Y
CY2017Q3 us-gaap Adjustment For Amortization
AdjustmentForAmortization
357000000
CY2017Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
357000000
CY2017Q3 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
31000000
CY2017Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
11000000
teva Impairments Restructuring And Others
ImpairmentsRestructuringAndOthers
2080000000
teva Valuation Allowances And Reserves Related To Current Period Sales
ValuationAllowancesAndReservesRelatedToCurrentPeriodSales
14546000000
teva Valuation Allowances And Reserves Related To Prior Period Sales
ValuationAllowancesAndReservesRelatedToPriorPeriodSales
-10000000
CY2017Q4 teva Brand Sales Of Palonosetron Iv Product
BrandSalesOfPalonosetronIvProduct
459000000
CY2009Q4 teva Annual Sales Of Namenda
AnnualSalesOfNamenda
1100000000
CY2005Q2 teva Annual Sales Of Niaspan
AnnualSalesOfNiaspan
416000000
CY2013Q3 teva Annual Sales Of Niaspan
AnnualSalesOfNiaspan
1100000000
CY2008Q3 teva Annual Sales Of Aggrenox
AnnualSalesOfAggrenox
340000000
CY2012Q3 teva Annual Sales Of Actos
AnnualSalesOfActos
2800000000
CY2012Q3 teva Annual Sales Of Actoplus
AnnualSalesOfActoplus
430000000
CY2010Q4 teva Annual Sales Of Actos
AnnualSalesOfActos
3700000000
CY2010Q4 teva Annual Sales Of Actoplus
AnnualSalesOfActoplus
500000000
CY2014Q4 teva Nexium Settlement Payment
NexiumSettlementPayment
24000000
CY2017 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 Segment
CY2017 teva Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Deferred Tax Liability Provisional Income Tax Benefit
TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxBenefit
112000000
CY2015Q1 teva Annual Sales Of Velcade
AnnualSalesOfVelcade
94000000
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
59000000 shares
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
798000000
CY2017Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
809000000
CY2017Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2967000000
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.52
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.52
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
372000000
CY2017Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
408000000
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
119000000
CY2017Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-3000000
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-494000000
CY2017Q3 us-gaap Gross Profit
GrossProfit
2650000000
CY2017Q3 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
355000000
CY2017Q3 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
20000000
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
530000000
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-259000000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
595000000
CY2017Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
15000000
CY2017Q3 us-gaap Other Comprehensive Income Loss Finalization Of Pension And Non Pension Postretirement Plan Valuation Net Of Tax
OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax
1000000
CY2017Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
199000000
CY2017Q3 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax
49000000
CY2017Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
264000000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
378000000
CY2017Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-17000000
CY2017Q3 us-gaap Other Income
OtherIncome
4000000
CY2017Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
65000000
CY2017Q3 us-gaap Profit Loss
ProfitLoss
610000000
CY2017Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
531000000
CY2017Q3 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
27000000
CY2017Q3 us-gaap Restructuring Charges
RestructuringCharges
72000000
CY2017Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5617000000
CY2017Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
843000000
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1017000000 shares
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1017000000 shares
CY2017Q3 teva Other Operating Income Net
OtherOperatingIncomeNet
4000000
CY2017Q3 teva Contingent Consideration Related Costs
ContingentConsiderationRelatedCosts
18000000
CY2017Q3 teva Forward Starting Interest Rate Swaps And Treasury Lock Agreements Losses
ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses
7000000
CY2017Q3 teva Gain From Currency Swap
GainFromCurrencySwap
4000000
CY2017Q3 teva Interest Rate Swap Gain
InterestRateSwapGain
2000000
CY2017Q3 teva Costs Related To Regulatory Actions Taken In Facilities
CostsRelatedToRegulatoryActionsTakenInFacilities
-1000000
CY2017Q3 teva Legal Settlements Loss Contingencies Impairments Other Expenses
LegalSettlementsLossContingenciesImpairmentsOtherExpenses
21000000
CY2017Q3 teva Impairment And Restructuring
ImpairmentAndRestructuring
550000000
CY2017Q3 teva Legal Settlements And Loss Contingencies
LegalSettlementsAndLossContingencies
-20000000
CY2017Q3 teva Purchase Of Research And Development In Process
PurchaseOfResearchAndDevelopmentInProcess
150000000
CY2017Q3 teva Other Unallocated Amounts
OtherUnallocatedAmounts
56000000
CY2017Q3 teva Impairments Restructuring And Others
ImpairmentsRestructuringAndOthers
550000000
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
66000000 shares
CY2018Q3 us-gaap Adjustment For Amortization
AdjustmentForAmortization
297000000
CY2018Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
297000000
CY2018Q3 us-gaap Business Combination Integration Related Costs
BusinessCombinationIntegrationRelatedCosts
4000000
CY2018Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-26000000
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-255000000
CY2018Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-281000000
CY2018Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2508000000
CY2018Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.12 pure
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2018Q3 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
1000000
CY2018Q3 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
31000000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
309000000
CY2018Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
521000000
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-213000000
CY2018Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-10000000
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-26000000
CY2018Q3 us-gaap Gross Profit
GrossProfit
2021000000
CY2018Q3 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
519000000
CY2018Q3 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
19000000
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-273000000
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-229000000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-208000000
CY2018Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
11000000
CY2018Q3 us-gaap Other Comprehensive Income Loss Finalization Of Pension And Non Pension Postretirement Plan Valuation Net Of Tax
OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax
1000000
CY2018Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-84000000
CY2018Q3 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax
-19000000
CY2018Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-105000000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
16000000
CY2018Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1000000
CY2018Q3 us-gaap Other Income
OtherIncome
35000000
CY2018Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
65000000
CY2018Q3 us-gaap Profit Loss
ProfitLoss
-197000000
CY2018Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
311000000
CY2018Q3 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
31000000
CY2018Q3 us-gaap Restructuring Charges
RestructuringCharges
88000000
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4529000000
CY2018Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
743000000
CY2018Q3 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
2000000
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1018000000 shares
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1018000000 shares
CY2018Q3 teva Other Operating Income Net
OtherOperatingIncomeNet
2000000
CY2018Q3 teva Contingent Consideration Related Costs
ContingentConsiderationRelatedCosts
29000000
CY2018Q3 teva Forward Starting Interest Rate Swaps And Treasury Lock Agreements Losses
ForwardStartingInterestRateSwapsAndTreasuryLockAgreementsLosses
7000000
CY2018Q3 teva Gain From Currency Swap
GainFromCurrencySwap
6000000
CY2018Q3 teva Interest Rate Swap Gain
InterestRateSwapGain
2000000
CY2018Q3 teva Costs Related To Regulatory Actions Taken In Facilities
CostsRelatedToRegulatoryActionsTakenInFacilities
1000000
CY2018Q3 teva Legal Settlements Loss Contingencies Impairments Other Expenses
LegalSettlementsLossContingenciesImpairmentsOtherExpenses
16000000
CY2018Q3 teva Impairment And Restructuring
ImpairmentAndRestructuring
658000000
CY2018Q3 teva Legal Settlements And Loss Contingencies
LegalSettlementsAndLossContingencies
19000000
CY2018Q3 teva Purchase Of Research And Development In Process
PurchaseOfResearchAndDevelopmentInProcess
60000000
CY2018Q3 teva Provisions For Income Taxes
ProvisionsForIncomeTaxes
40000000
CY2018Q3 teva Other Unallocated Amounts
OtherUnallocatedAmounts
84000000
CY2018Q3 teva Patented Medicines Regulations And Similar Payments
PatentedMedicinesRegulationsAndSimilarPayments
1000000
CY2018Q3 teva Impairments Restructuring And Others
ImpairmentsRestructuringAndOthers
658000000

Files In Submission

Name View Source Status
0001193125-18-315734-index-headers.html Edgar Link pending
0001193125-18-315734-index.html Edgar Link pending
0001193125-18-315734.txt Edgar Link pending
0001193125-18-315734-xbrl.zip Edgar Link pending
d599127d10q.htm Edgar Link pending
d599127dex101.htm Edgar Link pending
d599127dex311.htm Edgar Link pending
d599127dex312.htm Edgar Link pending
d599127dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g599127g1031203143717.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
teva-20180930.xml Edgar Link completed
teva-20180930.xsd Edgar Link pending
teva-20180930_cal.xml Edgar Link unprocessable
teva-20180930_def.xml Edgar Link unprocessable
teva-20180930_lab.xml Edgar Link unprocessable
teva-20180930_pre.xml Edgar Link unprocessable